PY1991606A - Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) - Google Patents
Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb)Info
- Publication number
- PY1991606A PY1991606A PY201901991606A PY1991606A PY1991606A PY 1991606 A PY1991606 A PY 1991606A PY 201901991606 A PY201901991606 A PY 201901991606A PY 1991606 A PY1991606 A PY 1991606A PY 1991606 A PY1991606 A PY 1991606A
- Authority
- PY
- Paraguay
- Prior art keywords
- hbv
- virus
- pyridines
- pyrazole
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere en general a nuevos agentes antivirales. Específicamente, la presente invención se refiere a compuestos que pueden inhibir las proteínas codificadas por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, composiciones que comprenden dichos compuestos, métodos para inhibir la replicación viral del VHB, métodos para tratar o prevenir la infección por el VHB, y procesos e intermedios para hacer los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000874 | 2018-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY1991606A true PY1991606A (es) | 2022-02-10 |
Family
ID=64362284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY201901991606A PY1991606A (es) | 2018-11-02 | 2019-10-31 | Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220009922A1 (es) |
| EP (1) | EP3873899A1 (es) |
| JP (1) | JP2022512873A (es) |
| KR (1) | KR20210098984A (es) |
| CN (1) | CN112969702A (es) |
| AR (1) | AR116946A1 (es) |
| AU (1) | AU2019373677B2 (es) |
| CA (1) | CA3118379A1 (es) |
| EA (1) | EA202191220A1 (es) |
| IL (1) | IL282687A (es) |
| PH (1) | PH12021550977A1 (es) |
| PY (1) | PY1991606A (es) |
| SG (1) | SG11202104080UA (es) |
| TW (1) | TW202031655A (es) |
| UY (1) | UY38439A (es) |
| WO (1) | WO2020089452A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38437A (es) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
| JPWO2025075020A1 (es) * | 2023-10-04 | 2025-04-10 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| WO2001006840A1 (en) | 1999-04-23 | 2001-02-01 | Jonathan Dallas Toye | Sheet fastening and anchoring component |
| AU3009801A (en) | 1999-12-22 | 2001-07-03 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
| EP1526852A1 (en) | 2002-07-25 | 2005-05-04 | Pharmacia Italia S.p.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| JP5977347B2 (ja) | 2011-07-01 | 2016-08-24 | バルーク エス.ブルームバーグ インスティテュート | Hbv感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| BR112015028873A2 (pt) | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
| DK2997019T3 (en) | 2013-05-17 | 2018-12-03 | Janssen Sciences Ireland Uc | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| WO2015057945A1 (en) | 2013-10-18 | 2015-04-23 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
| WO2015073774A1 (en) | 2013-11-14 | 2015-05-21 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis b infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2015133428A1 (ja) | 2014-03-06 | 2015-09-11 | 株式会社テイエルブイ | 蒸気システム |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| ES2748029T3 (es) | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| CN104945395B (zh) | 2014-03-28 | 2018-01-23 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CA2948580A1 (en) | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
| BR112017002970B1 (pt) | 2014-08-14 | 2023-04-11 | F. Hoffmann-La Roche Ag | Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
| CN107406378A (zh) | 2014-12-02 | 2017-11-28 | 诺维拉治疗公司 | 用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物 |
| WO2016109684A2 (en) | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| CA2979490C (en) | 2015-03-16 | 2023-07-18 | F. Hoffmann-La Roche Ag | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016177655A1 (en) | 2015-05-04 | 2016-11-10 | F. Hoffmann-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| CN107849037B (zh) | 2015-07-21 | 2020-04-17 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物 |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| AU2016340527B2 (en) * | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6523566B2 (ja) | 2015-11-04 | 2019-06-05 | チールー ファーマシューティカル カンパニー、リミテッド | ジヒドロピリド環化合物の結晶形、製造方法および中間体 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| WO2017198744A1 (en) | 2016-05-20 | 2017-11-23 | F. Hoffmann-La Roche Ag | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| EP3478692B1 (en) * | 2016-06-29 | 2020-06-17 | Novira Therapeutics Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JP7034133B2 (ja) | 2016-07-14 | 2022-03-11 | エフ.ホフマン-ラ ロシュ アーゲー | 感染性疾患の処置のためのカルボキシ 6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物 |
| WO2018011163A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018052967A1 (en) | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| CA3055194A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
-
2019
- 2019-10-31 AR ARP190103178A patent/AR116946A1/es not_active Application Discontinuation
- 2019-10-31 UY UY0001038439A patent/UY38439A/es not_active Application Discontinuation
- 2019-10-31 PY PY201901991606A patent/PY1991606A/es unknown
- 2019-11-01 CN CN201980072932.8A patent/CN112969702A/zh active Pending
- 2019-11-01 KR KR1020217016295A patent/KR20210098984A/ko not_active Ceased
- 2019-11-01 SG SG11202104080UA patent/SG11202104080UA/en unknown
- 2019-11-01 US US17/290,354 patent/US20220009922A1/en not_active Abandoned
- 2019-11-01 WO PCT/EP2019/079958 patent/WO2020089452A1/en not_active Ceased
- 2019-11-01 EP EP19801503.4A patent/EP3873899A1/en not_active Withdrawn
- 2019-11-01 JP JP2021523661A patent/JP2022512873A/ja active Pending
- 2019-11-01 EA EA202191220A patent/EA202191220A1/ru unknown
- 2019-11-01 AU AU2019373677A patent/AU2019373677B2/en not_active Expired - Fee Related
- 2019-11-01 CA CA3118379A patent/CA3118379A1/en not_active Abandoned
- 2019-11-01 PH PH1/2021/550977A patent/PH12021550977A1/en unknown
- 2019-11-01 TW TW108139835A patent/TW202031655A/zh unknown
-
2021
- 2021-04-27 IL IL282687A patent/IL282687A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3118379A1 (en) | 2020-05-07 |
| US20220009922A1 (en) | 2022-01-13 |
| WO2020089452A1 (en) | 2020-05-07 |
| AU2019373677A1 (en) | 2021-05-27 |
| EA202191220A1 (ru) | 2021-07-29 |
| SG11202104080UA (en) | 2021-05-28 |
| TW202031655A (zh) | 2020-09-01 |
| UY38439A (es) | 2020-05-29 |
| KR20210098984A (ko) | 2021-08-11 |
| AU2019373677B2 (en) | 2022-03-31 |
| EP3873899A1 (en) | 2021-09-08 |
| AR116946A1 (es) | 2021-06-30 |
| JP2022512873A (ja) | 2022-02-07 |
| IL282687A (en) | 2021-06-30 |
| CN112969702A (zh) | 2021-06-15 |
| PH12021550977A1 (en) | 2022-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY1991601A (es) | Nuevas 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| MX2020004838A (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
| ECSP20029558A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb) | |
| ECSP21079317A (es) | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| PY1991603A (es) | Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| PY1991608A (es) | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb) | |
| PY1991606A (es) | Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb) | |
| ECSP21078893A (es) | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) | |
| PY1991611A (es) | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
| PH12021550978A1 (en) | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) | |
| CL2021002798A1 (es) | Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb) | |
| UY38681A (es) | Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |